Over the last 2 years the lives of millions have changed because of the emergence of
Coronavirus disease 2019 (COVID-19). Patients living with inflammatory bowel disease …

Background and objectives There are concerns about the serological responses to
Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) …

Methods Anti-SARS-CoV-2 vaccination was administrated to 809 IBD patients. Interviews
were conducted to report adverse events related to vaccination. Of these 809, 346 patients …

Objectives Immune responses following SARS-CoV-2 vaccination in patients with
inflammatory bowel disease (IBD) are not well characterized. The aims of this study were to …

Immune-modifying treatment in inflammatory bowel disease (IBD) impairs the humoral
response. The role of T lymphocytes in this setting is still unclear. This study aims to assess if …

Materials and Methods Effectiveness and safety of COVID-19 vaccine in patients with
inflammatory bowel disease treated with immunomodulatory or biological drugs (ESCAPE …

In Deutschland haben sich nach Angaben des RKI seit Beginn der SARS-CoV-2-Pandemie
ca. 38, 5 Mio. Menschen mit dem Virus infiziert, über 176 000 Meschen sind an COVID-19 …

Identification of inflammatory bowel disease quickly and accurately is motivated by the large
number of patients who come with pain in the abdomen and receive minimal treatment …

We would like to comment on the article, entitled “Reduced humoral response to two doses
of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD …

First, we would like to thank Dr. Sookaromdee and colleagues for the interest in our study [1].
Currently, there is general consensus on the strong utility of the COVID-19 vaccines …